These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32083035)

  • 41. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan.
    Mushtaq S; Mansoor A; Umar M; Khan A; Siddiqi S; Manzoor S
    J Med Virol; 2020 Dec; 92(12):3475-3487. PubMed ID: 32129507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The outcome of combined treatment with ombitasvir-paritaprevir-ritonavir, sofosbuvir with or without ribavirin as salvage therapy for Egyptian HCV experienced patients: A single center study.
    Ismail WA; Wadea FM
    Drug Discov Ther; 2018; 12(6):368-373. PubMed ID: 30674772
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
    Andrieux-Meyer I; Tan SS; Thanprasertsuk S; Salvadori N; Menétrey C; Simon F; Cressey TR; Said HRHM; Hassan MRA; Omar H; Tee HP; Chan WK; Kumar S; Thongsawat S; Thetket K; Avihingsanon A; Khemnark S; Yerly S; Ngo-Giang-Huong N; Siva S; Swanson A; Goyal V; Bompart F; Pécoul B; Murad S
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):448-458. PubMed ID: 33865507
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
    Hézode C; Lebray P; De Ledinghen V; Zoulim F; Di Martino V; Boyer N; Larrey D; Botta-Fridlund D; Silvain C; Fontaine H; D'Alteroche L; Leroy V; Bourliere M; Hubert-Fouchard I; Guyader D; Rosa I; Nguyen-Khac E; Fedchuk L; Akremi R; Bennai Y; Filipovics A; Zhao Y; Bronowicki JP
    Liver Int; 2017 Sep; 37(9):1314-1324. PubMed ID: 28177199
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.
    da Silva Sacerdote AB; Filgueira NA; de Barros Barreto S; Batista AD; Lopes EP
    Immunol Res; 2020 Jun; 68(3):111-117. PubMed ID: 32537670
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
    Fourati S; Guedj J; Chevaliez S; Nguyen THT; Roudot-Thoraval F; Ruiz I; Soulier A; Scoazec G; Varaut A; Poiteau L; Francois M; Mallat A; Hézode C; Pawlotsky JM
    Aliment Pharmacol Ther; 2018 Mar; 47(5):665-673. PubMed ID: 29271114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.
    Ruane PJ; Ain D; Stryker R; Meshrekey R; Soliman M; Wolfe PR; Riad J; Mikhail S; Kersey K; Jiang D; Massetto B; Doehle B; Kirby BJ; Knox SJ; McHutchison JG; Symonds WT
    J Hepatol; 2015 May; 62(5):1040-6. PubMed ID: 25450208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
    Leroy V; Angus P; Bronowicki JP; Dore GJ; Hezode C; Pianko S; Pol S; Stuart K; Tse E; McPhee F; Bhore R; Jimenez-Exposito MJ; Thompson AJ
    Hepatology; 2016 May; 63(5):1430-41. PubMed ID: 26822022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    Mohamed MS; Hanafy AS; Bassiony MAA; Hussein S
    Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1368-1372. PubMed ID: 28953002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
    Ridruejo E; Garcia-Agudo R; Mendizabal M; Aoufi-Rabih S; Dixit V; Silva M; Fabrizi F
    Nefrologia (Engl Ed); 2020; 40(1):46-52. PubMed ID: 31229261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence.
    Teegen EM; Dürr M; Maurer MM; Eurich F; Vollbort A; Globke B; Bahra M; Blaeker H; Pratschke J; Eurich D
    Transpl Infect Dis; 2019 Feb; 21(1):e13020. PubMed ID: 30375710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
    Tao YC; Deng R; Wang ML; Lv DD; Yuan M; Wang YH; Chen EQ; Tang H
    Virol J; 2018 Oct; 15(1):150. PubMed ID: 30285800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
    Omar H; El Akel W; Elbaz T; El Kassas M; Elsaeed K; El Shazly H; Said M; Yousif M; Gomaa AA; Nasr A; AbdAllah M; Korany M; Ismail SA; Shaker MK; Doss W; Esmat G; Waked I; El Shazly Y
    Aliment Pharmacol Ther; 2018 Feb; 47(3):421-431. PubMed ID: 29193226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
    Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
    Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Goel A; Bhargava R; Rai P; Aggarwal R
    Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
    Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
    World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
    Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
    World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.